The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

The disclosure relates to methods for a genetic and/or metabolic disorder that alters sorbitol metabolism or causes over production of sorbitol, such as SDH deficiency, hereditary neuropathy using aldose reductase inhibitors.

The present invention relates to a biocompatible polydopamine nanomotor capable of infiltrating a bladder wall in a biological environment and remaining inside a bladder for a long time.

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.

The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.

The oral concentrated additive Mixture will mask any odor being expelled from the mouth. The concentrate will be used in, but not limited to, a liquid form to be placed on the tongue. It also will be a concentrate to be added to any drinkable liquid to include water, any water based products as well as any soft drink. It also will be added to manufactured candy products as well as any chew-able products to included chewing gum as well as gummy products.

The proprietary ingredients will be stickily tailored to the manufacturer of the concentrate.

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Dry powder formulations for inhalation containing a combination of an anticholinergic, a long-acting beta.sub.2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.